Go back

Industry interest in rare diseases grows

The pharmaceutical industry has increased its investment in rare diseases research, in particular because EU and US orphan drugs laws offer incentives for drug development in the area, Science Business reports.

For example, the companies GlaxoSmithKline and Pfizer have set up dedicated research units in the area, and French company Sanofi acquired US rare diseases specialist Genzyme earlier this year.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.